Barbara Ellers‐Lenz

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Fabrice Barlési, Johan Vansteenkiste, David R. Spigel et al. · The Lancet Oncology · 2018 · 397 citations

Medicine, Oncology, Pharmacology +11

Efficacy of flupirtine on cognitive function in patients with CJD

Markus Otto, Lukas Cepek, Peter Ratzka et al. · Neurology · 2004 · 206 citations

Medicine, Neurology, Pharmacology +17

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial

Sandra P. D’Angelo, Shailender Bhatia, Andrew S. Brohl et al. · Journal for ImmunoTherapy of Cancer · 2020 · 197 citations · Full text

Medicine, Oncology, Pharmacology +17

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

Sandra P. D’Angelo, Célèste Lebbé, Laurent Mortier et al. · Journal for ImmunoTherapy of Cancer · 2021 · 140 citations · Full text

Medicine, Oncology, Pharmacology +17

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Yi‐Long Wu, Valentina Guarneri, Pei Jye Voon et al. · The Lancet Oncology · 2024 · 86 citations · Full text

Medicine, Oncology, Pharmacology +16